Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 11, 2010, Pages 1702-1705

  Song, Jie ^a   Li, Mei ^a   Tretiakova, Maria ^a   Salgia, Ravi ^b   Cagle, Philip T ^c,d   Husain, Aliya N ^a  

^a Departments of Pathology   (United States)

^b Departments of Pathology and Medicine   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAX5 PROTEIN, HUMAN; PAXILLIN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR PAX5;

ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; NEUROENDOCRINE TUMOR; PATHOLOGY; PHOSPHORYLATION; TISSUE MICROARRAY;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PAXILLIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; TISSUE ARRAY ANALYSIS;

EID: 78249280642     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Jafri N, Salgia R. Biology and novel therapeutics for neuroendocrine tumors of the lung. J Biol Regul Homeost Agents. 2004;18(3-4):275-290.
2. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6):529-553.
3. Travis WD, Gal AA, Colby TV, Klimstra DS, Falk R, Koss MN. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol. 1998;29(3):272-279.
4. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22(8):934-944.
5. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003;63(19):6272-6281.
6. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005;65(4):1479-1488.
7. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-1043.
8. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol. 2009;4(4):444-447.
9. Kanteti R, Nallasura V, Loganathan S, et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-met transcription. Lab Invest. 2009;89(3): 301-314.
10. Parr C, Davies G, Nakamura T, Matsumoto K, Mason MD, Jiang WG. The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Biochem Biophys Res Commun. 2001;285(5):1330-1337.
11. Jagadeeswaran R, Surawska H, Krishnaswamy S, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008;68(1):132-142.